Exelixis, Inc. - Common Stock (EXEL) stock analysis

EXEL · Exelixis, Inc. - Common Stock

Latest recorded price: USD 67.10

Model-estimated fair value: USD 53.17. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Biotechnology

At $67.10, EXEL trades 26.2% above the model's base-case value of $53.17. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $40.87 in the conservative case and $68.00 in the optimistic case, with a valuation confidence score of 55/100. Fiscal 2025 figures: revenue growth 12.9%, free cash flow margin 37.7%, ROIC 54.3%. The model does not flag any risk signals for this company.

Similar companies in Healthcare